Daily Trades
- Dylan Jovine
I recommend selling shares of Weight Watchers (SYM: WW) here at $4.50, a 35% loss from our recommended price of $7.01.
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
The Wall Street Journal calls this new drug “King Kong”…
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Lot of folks have written in to ask whether I still think Eli Lilly (SYM: LLY) is a buy up here.
- Dylan Jovine
This new drug is predicted to help as many as 132 million Americans live longer, healthier and happier lives.
- Dylan Jovine
They’re all talking about a new class of weight loss drugs, based on safe and proven diabetes drugs hitting the market: Ozempic, Wegovy and Mounjaro.
deal of the month
Categories
How I Got Into Biotech Stocks
My Journey Into Biotech Investing
Play it Safe & Take the Profits Off the Table
Recent posts
Tags
Connect with Us
- Dylan Jovine
I recommend selling shares of Weight Watchers (SYM: WW) here at $4.50, a 35% loss from our recommended price of $7.01.
- Dylan Jovine
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
- Dylan Jovine
The Wall Street Journal calls this new drug “King Kong”…
- Dylan Jovine
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
- Dylan Jovine
Lot of folks have written in to ask whether I still think Eli Lilly (SYM: LLY) is a buy up here.
- Dylan Jovine
This new drug is predicted to help as many as 132 million Americans live longer, healthier and happier lives.
- Dylan Jovine
They’re all talking about a new class of weight loss drugs, based on safe and proven diabetes drugs hitting the market: Ozempic, Wegovy and Mounjaro.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.
